Tempest Therapeutics's three largest insider shareholders as of September 09, 2026 are Thomas Woiwode (Director, 2.12Mn shares), Matthew Angel (Ceo And President, 231.48K shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 209.94K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas Woiwode | Director, TenPercentOwner | 0 | 2,118,644 | 2,118,644 | 81.7% | 03 May, 2022 |
| 2 | Matthew Angel | Ceo And President | 0 | 231,482 | 231,482 | 8.9% | 25 Mar, 2026 |
| 3 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 209,941 | 0 | 209,941 | 8.1% | 12 Aug, 2024 |
| 4 | Justin Trojanowski | Corporate Controller | 22,168 | 0 | 22,168 | 0.9% | 02 Jul, 2024 |
| 5 | Samuel Whiting | Chief Medical Officer | 9,573 | 0 | 9,573 | 0.4% | 03 Jul, 2024 |
| 6 | Thomas W. Dubensky | President | 39 | 0 | 39 | 0.0% | 11 Jan, 2022 |
| 7 | Stephen R Brady | President And Ceo | 16 | 0 | 16 | 0.0% | 08 Jul, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 04 Jun, 2026 | John D. Yee | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 04 Jun, 2026 | William Drake Richey | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 31 Mar, 2026 | Justin Trojanowski | Corporate Controller | Acquired A | 22,000 | $0.00 | $0 | 22,000 | Direct |
| 31 Mar, 2026 | Nicholas Maestas | Chief Financial Officer | Acquired A | 140,000 | $0.00 | $0 | 140,000 | Direct |
| 31 Mar, 2026 | Justin Trojanowski | Corporate Controller | Acquired A | 22,000 | $0.00 | $0 | 22,000 | Direct |
| 31 Mar, 2026 | Justin Trojanowski | Corporate Controller | Acquired A | 22,000 | $0.00 | $0 | 22,000 | Direct |
| 31 Mar, 2026 | Justin Trojanowski | Corporate Controller | Acquired A | 22,000 | $0.00 | $0 | 22,000 | Direct |
| 24 Mar, 2026 | Matthew Angel | Ceo And President | Acquired P | 231,482 | $2.16 | $500.00K | 231,482 | Indirect |
| 04 Feb, 2026 | Matthew Angel | Ceo And President | Acquired A | 269,621 | $0.00 | $0 | 269,621 | Direct |
| 27 Jan, 2026 | Geoffrey Nichol | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Michael Raab | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Ronit Simantov | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 27 Jan, 2026 | Christine A Pellizzari | Director | Acquired A | 1,230 | $0.00 | $0 | 1,230 | Direct |
| 02 Jan, 2025 | Stephen R Brady | President And Ceo | Acquired A | 550,000 | $0.00 | $0 | 188 | Direct |
| 02 Jan, 2025 | Justin Trojanowski | Corporate Controller | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 02 Jan, 2025 | Nicholas Maestas | Chief Financial Officer | Acquired A | 200,000 | $0.00 | $0 | 68 | Direct |
| 02 Jan, 2025 | Justin Trojanowski | Corporate Controller | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 02 Jan, 2025 | Samuel Whiting | Chief Medical Officer | Acquired A | 270,000 | $0.00 | $0 | 270,000 | Direct |
| 02 Jan, 2025 | Justin Trojanowski | Corporate Controller | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 02 Jan, 2025 | Samuel Whiting | Chief Medical Officer | Acquired A | 270,000 | $0.00 | $0 | 270,000 | Direct |